These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 1441334)
21. Considerations in performing virus spiking experiments and process validation studies. Darling AJ Dev Biol Stand; 1993; 81():221-9. PubMed ID: 8174806 [TBL] [Abstract][Full Text] [Related]
22. WHO Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser; 1994; 840():1-218. PubMed ID: 8203143 [No Abstract] [Full Text] [Related]
23. WHO Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser; 1989; 786():1-184. PubMed ID: 2511670 [No Abstract] [Full Text] [Related]
24. Blood components: current challenges. Rouger P Transfus Clin Biol; 2007 Dec; 14(6):496-8. PubMed ID: 18420438 [TBL] [Abstract][Full Text] [Related]
25. Criteria for the choice of viruses in validation studies. Minor PD Dev Biol Stand; 1993; 81():215-9. PubMed ID: 8174805 [TBL] [Abstract][Full Text] [Related]
26. Some problems associated with sterility testing in a commercial organization. Gasson AG Dev Biol Stand; 1974; 23():151-6. PubMed ID: 4459189 [No Abstract] [Full Text] [Related]
27. WHO Expert Committee on Biological Standardization. World Health Organ Tech Rep Ser; 1994; 848():1-90. PubMed ID: 7839693 [No Abstract] [Full Text] [Related]
28. Bacterial contamination of blood products. Palavecino E; Jacobs M; Yomtovian R Curr Hematol Rep; 2004 Nov; 3(6):450-5. PubMed ID: 15496280 [TBL] [Abstract][Full Text] [Related]
29. [Safety of blood and blood products in the face of recent reports on the transmissibility of Alzheimer's disease in an animal experiment]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Apr; 56(4):584. PubMed ID: 23529604 [No Abstract] [Full Text] [Related]
30. [Safety of blood and blood products in the face of recent reports on the transmissibility of Alzheimer's disease in an animal experiment. Explanation to comment]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2013 Apr; 56(4):585-9. PubMed ID: 23529605 [No Abstract] [Full Text] [Related]
33. British Blood Transfusion Society. Blood Component Special Interest Group Symposium. Towards 'purer and safer' blood components and blood products. London, United Kingdom, 5 May 1994. Abstracts. Clin Lab Haematol; 1994 Dec; 16(4):379-406. PubMed ID: 7736717 [No Abstract] [Full Text] [Related]
34. Viral safety of biological products in WHO policy. Grachev VP Dev Biol Stand; 1991; 75():241-6. PubMed ID: 1794628 [TBL] [Abstract][Full Text] [Related]
35. The regulation of medicinal products derived from human blood or plasma in the European Community. Brunko P Dev Biol Stand; 1993; 81():269-71. PubMed ID: 8174813 [No Abstract] [Full Text] [Related]
36. Validation of removal of human retroviruses. Marcus-Sekura CJ Dev Biol Stand; 1992; 76():215-23. PubMed ID: 1478339 [No Abstract] [Full Text] [Related]
37. Simultaneous contamination of transfusion blood with Enterobacter agglomerans and Pseudomonas fluorescens, supposedly from the pilot tubes. Felsby M; Munk-Andersen G; Siboni K J Med Microbiol; 1973 Aug; 6(3):413-6. PubMed ID: 4726336 [No Abstract] [Full Text] [Related]